本文選題：TACE + PMCT　； 參考：《西南醫(yī)科大學(xué)》2017年碩士論文

【摘要】：目的:通過(guò)對(duì)比經(jīng)動(dòng)脈導(dǎo)管灌注化療栓塞術(shù)(TACE)聯(lián)合微波消融術(shù)(PMCT)與單純TACE處理前后血清血管內(nèi)皮生長(zhǎng)因子(VEGF)、血清甲胎蛋白(AFP)、肝癌患者肝儲(chǔ)備功能的變化情況以及治療后病灶控制率、并發(fā)癥,探討TACE聯(lián)合PMCT治療肝惡性腫瘤的優(yōu)勢(shì);并通過(guò)比較兩組患者治療前后T淋巴細(xì)胞亞群的變化,探討PMCT對(duì)患者機(jī)體免疫功能的影響。方法:將我科2016年1月至2017年1月符合本研究入組標(biāo)準(zhǔn)的肝癌病人共78例次,分為實(shí)驗(yàn)組(TACE聯(lián)合PMCT組)和對(duì)照組(TACE組),其中實(shí)驗(yàn)組36例,對(duì)照組42例;兩組患者均予以TACE以及常規(guī)護(hù)肝降酶、抗乙肝病毒等基礎(chǔ)治療,實(shí)驗(yàn)組在TACE后5~7天進(jìn)行PMCT,分別在TACE術(shù)前1天、TACE或PMCT術(shù)后5天抽取外周血測(cè)量血清VEGF、AFP水平以及肝儲(chǔ)備功能即ICG R15(吲哚菁綠試驗(yàn)15min滯留率)以及T淋巴細(xì)胞亞群的變化;術(shù)后觀察兩組病人并發(fā)癥情況;術(shù)后1月復(fù)查AFP水平并行增強(qiáng)CT或MRI檢查,評(píng)估病灶的控制率(完全緩解+部分緩解+疾病穩(wěn)定)。結(jié)果:1、對(duì)照組TACE治療后血清VEGF濃度較治療前明顯升高,差異具有統(tǒng)計(jì)學(xué)意義(P0.05);實(shí)驗(yàn)組TACE聯(lián)合PMCT治療后血清VEGF濃度較治療前明顯下降,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。2、對(duì)照組42例患者中30例術(shù)前AFP水平升高的患者,術(shù)后1月復(fù)查AFP均有不同程度降低,其中4例(4/30,13.3%)患者恢復(fù)正常,12例(12/30,40.0%)患者下降≥50%;實(shí)驗(yàn)組36例患者中25例AFP水平升高的患者,術(shù)后1月復(fù)查AFP,均有不同程度降低,其中7例(7/25,28.0%)患者恢復(fù)正常,13例(13/25,52.0%)患者下降≥50%。實(shí)驗(yàn)組經(jīng)治療后AFP下降率明顯優(yōu)于對(duì)照組,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。3、對(duì)照組TACE治療后肝儲(chǔ)備功能吲哚菁綠15分鐘滯留率(ICG R15)較治療前明顯升高,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。實(shí)驗(yàn)組TACE聯(lián)合PMCT治療后肝儲(chǔ)備功能吲哚菁綠15分鐘滯留率(ICG R15)較前降低,差異具有統(tǒng)計(jì)學(xué)意義(P0.05)。4、對(duì)照組患者TACE治療后CD3+T細(xì)胞、CD4+T細(xì)胞水平及CD4+/CD8+比值均明顯下降,CD8+T細(xì)胞水平較治療前升高,差異具有統(tǒng)計(jì)學(xué)意義(P0.05);實(shí)驗(yàn)組患者TACE聯(lián)合PMCT治療后CD3+T細(xì)胞、CD4+T細(xì)胞水平及CD4+/CD8+比值均下降,CD8+T細(xì)胞水平較治療前升高,但差異無(wú)統(tǒng)計(jì)學(xué)意義(P0.05)。5、病灶控制率對(duì)比:根據(jù)世界衛(wèi)生組織(WHO)實(shí)體瘤測(cè)量標(biāo)準(zhǔn)進(jìn)行評(píng)價(jià)病灶控制率(完全緩解+部分緩解+疾病穩(wěn)定),其中實(shí)驗(yàn)組CR 7例,PR14例,SD 12例,PD 3例,控制率為91.7%(33/36);對(duì)照組CR 4例,PR 13例,SD 14例,PD 11例,控制率為73.8%(31/42)。實(shí)驗(yàn)組1月病灶控制率明顯高于對(duì)照組,差異有統(tǒng)計(jì)學(xué)意義(P0.05)。6、兩組患者除有惡心、嘔吐、發(fā)熱、疼痛等常見(jiàn)并發(fā)癥外,兩組各出現(xiàn)1例嚴(yán)重并發(fā)癥,對(duì)照組中出現(xiàn)1例(1/42,2.4%)膽汁瘤;實(shí)驗(yàn)組中出現(xiàn)1例(1/36,2.8%)膽道支氣管瘺,兩組間差異無(wú)統(tǒng)計(jì)學(xué)意義。結(jié)論:1、TACE治療會(huì)損害肝臟功能,PMCT治療對(duì)肝臟的功能影響不大;2、TACE治療對(duì)肝癌患者的細(xì)胞免疫具有一定的損害,而PMCT可在一定程度上提高患者細(xì)胞免疫;3、TACE與PMCT治療肝癌相互補(bǔ)充,二者聯(lián)合具有安全、實(shí)用、有效、優(yōu)勢(shì)互補(bǔ)的特點(diǎn),可提高肝癌患者的療效,減少轉(zhuǎn)移和復(fù)發(fā),具有一定的臨床推廣價(jià)值。
[Abstract]:Objective: To compare the changes of serum vascular endothelial growth factor (VEGF), serum alpha fetoprotein (AFP) and liver reserve function in patients with liver cancer before and after transcatheter arterial catheter perfusion chemotherapy (TACE) combined with microwave ablation (PMCT) and simple TACE treatment, and the control rate and complications after treatment, and discuss the combination of TACE and PMCT in the treatment of liver malignancies. By comparing the changes of T lymphocyte subsets before and after treatment in two groups of patients, and to explore the effect of PMCT on the immune function of the patients. Methods: 78 cases of liver cancer patients who were in accordance with the standard of this study from January 2016 to January 2017 were divided into the experimental group (TACE combined PMCT group) and the control group (group TACE), of which 36 cases were in the experimental group, The control group had 42 cases; the two groups were treated with TACE, conventional liver protection, anti HBV and other basic treatments. The experimental group performed PMCT on 5~7 days after TACE. The serum VEGF, AFP level and ICG R15 (indocyanine green test 15min retention) and lymph fines were taken at 1 days before TACE and 5 days after TACE or PMCT respectively. Changes in the cell subgroup; after the operation, the complications were observed in two groups of patients. After the reexamination of AFP level in January and the CT or MRI examination, the control rate of the focus (complete remission + partial remission + disease stability). Results: 1, the serum VEGF concentration in the control group was significantly higher than before the treatment (P0.05); the experimental group TACE combined with TACE. The concentration of serum VEGF decreased significantly after treatment with PMCT, and the difference was statistically significant (P0.05).2. In the 42 patients in the control group, 30 cases with higher AFP level before operation were reduced in different degrees in January, of which 4 cases (4/30,13.3%) were restored to normal, 12 cases (12/30,40.0%) decreased more than 50%, and 2 of the 36 patients in the experimental group were 2. In 5 patients with elevated AFP level, AFP was reviewed in January, and 7 cases (7/25,28.0%) were restored to normal, and 13 cases (13/25,52.0%) were significantly better than the control group after treatment. The difference was statistically significant (P0.05).3, and the liver reserve function of indocyanine green 15 after TACE treatment in the control group. The rate of clock retention (ICG R15) was significantly higher than that before the treatment (P0.05). The 15 minute retention rate of indocyanine green (ICG R15) after TACE combined with PMCT in the experimental group was lower than that before, and the difference was statistically significant (P0.05).4. The CD3+T cells in the control group were treated with TACE, and the CD4+T cell level and the ratio were all clear. The level of CD8+T cell was significantly higher than that before the treatment (P0.05). The level of CD3+T cells, CD4+T cell level and CD4+/CD8+ ratio decreased after TACE combined with PMCT in the experimental group, and the level of CD8+T cells was higher than that before the treatment, but the difference was not statistically significant (P0.05).5, the control rate of the lesion was compared: according to WHO (WHO) Solid tumor measurement standard was used to evaluate the control rate of focus (complete remission + partial remission + disease stability). In the experimental group, CR 7 cases, PR14 cases, SD 12 cases, PD 3 cases, control rate 91.7% (33/36), control group CR 4 cases, PR 13 cases, SD 14 cases, PD 11 cases, and the control rate is 73.8% (31/42). In the experiment group in January, the focus control rate was obviously higher than the control group, the difference has statistics Learning significance (P0.05).6, two groups of patients, except for nausea, vomiting, fever, pain and other common complications, the two groups of 1 cases of severe complications, 1 cases in the control group (1/42,2.4%) cholangioma, 1 cases (1/36,2.8%) biliary fistula in the experimental group, the two groups have no statistically significant difference. Conclusion: 1, TACE treatment will damage liver function, PMCT treatment 2, TACE treatment has certain damage to the cell immunity of the patients with liver cancer, and PMCT can improve the cell immunity of patients to some extent; 3, TACE and PMCT are complementary to the liver cancer. The two combination is safe, practical, effective and complementary, which can improve the curative effect of liver cancer patients and reduce the metastasis and relapse. Hair has certain clinical value.

【學(xué)位授予單位】：西南醫(yī)科大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2017
【分類(lèi)號(hào)】：R735.7

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 朱楠;魯東;肖景坤;呂維富;;肝動(dòng)脈化療栓塞聯(lián)合射頻消融術(shù)治療中晚期肝癌的療效[J];中國(guó)介入影像與治療學(xué);2017年04期

2 沈楨;閻皓;;大功率微波消融聯(lián)合動(dòng)脈化療栓塞介入治療中大肝癌療效及安全性研究[J];解放軍醫(yī)藥雜志;2016年10期

3 王延明;王能;許峗;沈強(qiáng);錢(qián)國(guó)軍;;微波消融治療7403例肝癌的嚴(yán)重并發(fā)癥[J];中華肝膽外科雜志;2016年10期

4 楊沛華;丁紅兵;周觀林;許飛;;經(jīng)肝動(dòng)脈化療栓塞聯(lián)合經(jīng)皮微波消融序貫治療早期肝癌效果分析[J];當(dāng)代醫(yī)學(xué);2016年27期

5 魏曉榮;;肝腫瘤消融相關(guān)膽道出血的臨床表現(xiàn)及治療[J];世界最新醫(yī)學(xué)信息文摘;2016年55期

6 馬英;孫韜;李玉苓;孔麗;;原發(fā)性肝癌TACE術(shù)后射頻消融聯(lián)合生物治療對(duì)免疫功能及血管內(nèi)皮生長(zhǎng)因子的影響研究[J];河北醫(yī)藥;2016年12期

7 鄧興;胡鴻;游箭;廖運(yùn)國(guó);文曉霞;趙曉偉;;TACE聯(lián)合微波消融治療原發(fā)性肝癌的效果分析[J];西部醫(yī)學(xué);2016年04期

8 趙鵬;鄭加生;張洪海;袁春旺;崔石昌;杜寧;趙隸贏;;肝動(dòng)脈導(dǎo)管化療栓塞聯(lián)合CT引導(dǎo)精準(zhǔn)微波消融治療原發(fā)性肝癌的療效及影響因素[J];中華腫瘤雜志;2016年02期

9 張志剛;劉新民;;膽管支氣管瘺的治療:6例報(bào)告并文獻(xiàn)回顧[J];中國(guó)微創(chuàng)外科雜志;2016年01期

10 生守鵬;鄭加生;崔石昌;錢(qián)智玲;崔雄偉;李建軍;;肝腫瘤消融相關(guān)膽道出血的臨床表現(xiàn)及治療[J];中國(guó)介入影像與治療學(xué);2016年01期

相關(guān)碩士學(xué)位論文 前4條

1 楊巧麗;諾帝—褐藻酸鈉微球治療兔VX2肝癌的實(shí)驗(yàn)研究[D];四川醫(yī)科大學(xué);2015年

2 王艷玲;IER5在輻射及順鉑誘導(dǎo)人肝癌HepG_2細(xì)胞凋亡中的作用[D];河北醫(yī)科大學(xué);2011年

3 王芳;肝癌患者調(diào)節(jié)性T細(xì)胞及其免疫狀態(tài)的研究[D];天津醫(yī)科大學(xué);2010年

4 吳振州;肝癌射頻消融術(shù)前后CD3~+T細(xì)胞、CD4~+T細(xì)胞、CD8~+T細(xì)胞、CD4~+/CD8~+T細(xì)胞比值變化的Meta分析[D];河北醫(yī)科大學(xué);2010年

，

本文編號(hào)：1833899